BRIEF published on 09/26/2024 at 19:05, 1 year 2 months ago Enlighta Inc. Announces Resignation of Director and President Resignation Leadership Change Enlighta Inc. Norman Tsui Stem Cell Isolation
BRIEF published on 09/26/2024 at 19:05, 1 year 2 months ago Enlighta Inc. annonce la démission de son directeur et de son président Changement De Direction Démission Enlighta Inc. Norman Tsui Isolement Des Cellules Souches
PRESS RELEASE published on 09/26/2024 at 19:00, 1 year 2 months ago Enlighta Inc. Announces Resignation of Director and President Enlighta Inc. founder and President Norman Tsui resigns from his position, offering to assist in the transition phase. The Board expresses gratitude for his contribution to the company's success Resignation Technology Company Leadership Enlighta Inc. Norman Tsui
PRESS RELEASE published on 03/01/2023 at 19:30, 2 years 9 months ago Enlighta Announces Appointment Of CFO
PRESS RELEASE published on 02/09/2023 at 14:00, 2 years 9 months ago Enlighta Inc. Announces Transfer to NEX
Published on 12/05/2025 at 02:35, 4 hours 2 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 37 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 32 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 37 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 7 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 12 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 22 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 27 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 22 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 37 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 52 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
